Disease Volume and Oligometastatic Subgroup Insights in Metastatic Castration-Sensitive Prostate Cancer

In this segment, Dr. Graham and Dr. Sokolova discuss the role of subgroup analyses in metastatic castration-sensitive prostate cancer, with a focus on disease volume and oligometastatic presentations. The conversation explores how these subgroup data have become increasingly relevant in treatment planning and clinical discussions. Dr. Graham highlights the need to carefully interpret subgroup findings, recognizing both their potential value and their limitations. Both experts emphasize that disease volume and metastatic burden can inform, but should not solely determine, treatment decisions in routine practice. The discussion underscores the importance of integrating subgroup data with individual patient characteristics, clinical judgment, and overall treatment goals. Overall, this segment illustrates how clinicians thoughtfully apply subgroup insights to personalize management strategies while avoiding overinterpretation of exploratory analyses in mCSPC.